Xenon Pharmaceuticals (XENE) is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder ...
Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure ...
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- . (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage ...
Immunome’s investigational oral therapy has slashed the risk of disease progression or death by 84% for patients with desmoid ...
Zenas's strong balance sheet, with $301.6M in cash and runway into late 2026, supports aggressive late-stage pipeline ...
In a circular issued on December 24, the RBI said the second phase of the Continuous Clearing and Settlement (CCS) framework has been postponed, while Phase 1 will continue to operate as currently ...
Acrivon Therapeutics, Inc. ('Acrivon” or 'Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company ...
KINGSTOWN, St. Vincent and Grenadines, Dec. 12, 2025 (GLOBE NEWSWIRE) -- ...
Two private rail operators have publicly expressed interest in operating on the northern Shenandoah Valley’s dormant rail ...
The Wuthering Waves 3.0 update is finally available for PC, PS5, and mobile devices. The latest patch added the ...
The anti-CD40 antibody tegoprubart offers a tacrolimus-free immunosuppression option for preventing islet transplant ...
Mutuum Finance gains momentum as Phase 6 nears full sellout, driving price projections into 2026 and positioning MUTM as a high-upside DeFi contender.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback